Conference
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
Authors
Petrylak DP; Heath EI; Sonpavde G; George S; Morgans AK; Eigl BJ; Picus J; Cheng SY; Hotte SJ; Gartner EM
Volume
34
Pagination
pp. 4532-4532
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2016
DOI
10.1200/jco.2016.34.15_suppl.4532
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X